![Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0920996413003411-gr1.jpg)
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect
![Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fnpjschz.2015.39/MediaObjects/41537_2015_Article_BFnpjschz201539_Fig1_HTML.jpg)
Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia
![Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0920996413003411-gr2.jpg)
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect
![Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics | Advances in Therapy Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics | Advances in Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-020-01566-w/MediaObjects/12325_2020_1566_Fig1_HTML.png)
Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics | Advances in Therapy
![A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder | CNS Drugs A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder | CNS Drugs](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40263-023-00996-8/MediaObjects/40263_2023_996_Fig3_HTML.png)
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder | CNS Drugs
![Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics | Advances in Therapy Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics | Advances in Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-020-01566-w/MediaObjects/12325_2020_1566_Figa_HTML.png)
Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics | Advances in Therapy
![Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial - The Lancet Psychiatry Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial - The Lancet Psychiatry](https://www.thelancet.com/cms/asset/7762d38f-8b7a-4b5c-a44f-5a4bc7cca2a3/gr1.gif)
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial - The Lancet Psychiatry
![Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms | Pharmacological Reports Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms | Pharmacological Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs43440-022-00440-6/MediaObjects/43440_2022_440_Fig1_HTML.png)
Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms | Pharmacological Reports
![PDF] Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics | Semantic Scholar PDF] Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9971933d7b6c167361ab8cd829680d1cbf9cc46b/2-Figure1-1.png)
PDF] Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics | Semantic Scholar
![Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study | Psychiatrist.com Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study | Psychiatrist.com](https://www.psychiatrist.com/PublishingImages/19m12835F1.jpg)
Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study | Psychiatrist.com
![Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/20r02799T1.gif)